A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Rebecca S KristeleitRuth PlummerRobert JonesLouise CarterSarah P BlagdenDebashis SarkerTobias ArkenauThomas R Jeffry EvansSarah DansonStefan N SymeonidesGareth J VealBarbara J KlenckeMark M KowalskiUdai BanerjiPublished in: British journal of cancer (2023)
Clinicaltrials.gov NCT02797964.